Live Biotherapeutics Drug Discovery Services for Ulcerative Colitis (UC)
Probiotics might offer an alternative or adjuvant approach to conventional therapy of ulcerative colitis (UC) by altering the intestinal microflora and modulating the host immune system. At Creative Biolabs, we offer one-stop solutions for probiotic drug development and characterization to promote the identification of probiotic drugs to meet your specific project demands.
Introduction of UC
UC is a chronic inflammatory bowel disease of unknown etiology that is characterized by diffuse mucosal inflammation of the colon and acute exacerbations followed by remissions. Patients usually present with debilitating symptoms such as bloody diarrhoea, abdominal pain, urgency, or tenesmus. The pathogenesis of UC likely involves the interplay of different factors, including the genetic factors, environment, the gut microbiota, and the immune system. Current medical management involves a variety of treatments, including aminosalicylates, corticosteroids, and immunosuppressant agents, that suppress intestinal inflammation associated with UC. However, prolonged use of chemicals may result in potential adverse events. Hence, new alternative therapeutic approaches for the treatment of UC are constantly being sought. Recently, probiotic therapy has been recognized to be safe and effective for patients with UC.
Treatment of UC with Probiotics
Although the etiology is still unclear, UC development might be caused by an imbalance between intestinal microbiota and mucosal immunity, resulting in excessive intestinal inflammation. Intestinal microflora has long been implicated as an important initiating factor in the pathogenesis of UC. In this perspective, probiotics have been proposed as an alternative treatment option that is thought to alter the growth of bacteria in the bowel and reduce inflammation. Many studies have examined the effects of specific bacterial strains or species in the treatment of UC, which include but not limited to:
Several studies have reported that probiotics such as the probiotic drug, bifidobacterium-fermented milk, and E. coli Nissle 1917, could be used to maintain clinical remission and prevent relapse in patients with UC. Unlike most probiotic products that are composed of either single microbes or a combination of a few microbes, the probiotic drug is a high-concentration probiotic preparation of 8 bacterial strains, including 4 strains of Lactobacilli, 3 strains of Bifidobacteria, and Streptococcus thermophilus. Although their mechanisms of action have not been established, some studies suggest that the probiotic drug modulates membrane permeability and the mucosal immune system and is an effective treatment against active UC. Moreover, some evidence showed that E. coli Nissle 1917 provides significant benefits for the prevention and treatment of mild to moderate UC. Taken together, these data suggest that treatment with probiotics could be a promising therapeutic option for patients with active UC.
Probiotic Drug Discovery Services at Creative Biolabs
With over ten years' extensive experience and advanced platforms, our scientists are confident in offering probiotic drug discovery services in a high-quality manner. Our comprehensive services include but not limited to probiotic drug development and qualification, services.
Creative Biolabs is one of the well-recognized experts who are professionals in the field of next-generation probiotics (NGPs). If there are any questions, please do not hesitate to contact us for more information.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
